Comparing Drug abelacimab relative to apixaban on venous

Recruiting

18-99 years

All

10 participants needed

1 Location

Brief description of study

The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of $1000.00 (10 total visits).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: venous thromboembolism,VTE
Age: Between 18 Years - 99 Years
Gender: All

Updated on 01 Aug 2024. Study ID: 851767

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Comparing Drug abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study